All News Kazia Therapeutics Limited

Equities

KZIA

US48669G1058

Market Closed - Nasdaq Other stock markets 02:00:01 24/05/2024 am IST			5-day change	1st Jan Change
0.27 ^USD	-4.34%		-2.74%	-38.57%

01/05	Kazia Therapeutics Limited Reports Successful Stage 1 Completion of the EVT801 Phase 1 Clinical Trial in Advanced Cancer Patients	CI
19/04	Kazia Therapeutics Limited announced that it expects to receive $15 million in funding from Alumni Capital LP	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kazia Therapeutics : Securities Purchase Agreement - Form 6-K	18/05	PU
KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS	01/05	PR
Kazia Therapeutics Limited Reports Successful Stage 1 Completion of the EVT801 Phase 1 Clinical Trial in Advanced Cancer Patients	01/05	CI
Kazia Therapeutics : Purchase Agreement - Form 6-K	20/04	PU
Kazia Therapeutics Limited announced that it expects to receive $15 million in funding from Alumni Capital LP	19/04	CI
Kazia Therapeutics : Corporate Presentation	12/04	PU
Kazia Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	27/03	CI
Kazia Therapeutics : Half Yearly Report - 31 December 2023 - Form 6-K	27/03	PU
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases	21/03	PR
Kazia Therapeutics Limited Enters into an Exclusive Licensing Agreement Withsovargen Co., Ltd	21/03	CI
Kazia Therapeutics : EVT801 Progress Update Presentation	20/03	PU
Stocks Making Waves: Insights into Key Developments and Potential VTAK, TBIO, OCEA, ONMD, KZIA	27/02	AQ
Kazia Therapeutics' Lead Drug Candidate Meets Goal of Early-Stage Study	22/02	MT
Kazia Therapeutics Limited Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint	21/02	CI
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024 (Updated)	21/02	AQ
Certain Warrants of Kazia Therapeutics Limited are subject to a Lock-Up Agreement Ending on 4-FEB-2024.	04/02	CI
Certain Ordinary Shares of Kazia Therapeutics Limited are subject to a Lock-Up Agreement Ending on 4-FEB-2024.	04/02	CI
Certain American Depositary Shares of Kazia Therapeutics Limited are subject to a Lock-Up Agreement Ending on 4-FEB-2024.	04/02	CI
KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS	18/01	PR
Kazia Therapeutics Limited Announces Appointment of Board Members	18/01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Kazia Therapeutics Limited

Equities

KZIA

US48669G1058

All News

Filters